Free Trial
Invest Smarter with A.I. PowerStart My Trial

Starpharma (OTCMKTS:SPHRY) Trading 3.6% Higher - Still a Buy?

Written by MarketBeat
September 26, 2025
Starpharma logo with Medical background

Key Points

  • Starpharma Holdings Ltd. saw a 3.6% increase in stock price, trading at $1.45, despite a significant drop in trading volume.
  • The company has a strong financial position with a debt-to-equity ratio of 0.06 and a current ratio of 4.32, indicating good liquidity.
  • Starpharma specializes in biopharmaceuticals, offering products like VivaGel and VIRALEZE, which target bacterial vaginosis and viral infections.
  • Five stocks we like better than Starpharma.

Starpharma Holdings Ltd. (OTCMKTS:SPHRY - Get Free Report) shot up 3.6% during trading on Friday . The company traded as high as $1.45 and last traded at $1.45. 1,676 shares changed hands during mid-day trading, a decline of 43% from the average session volume of 2,964 shares. The stock had previously closed at $1.40.

Starpharma Stock Up 3.6%

The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.95. The firm has a 50 day moving average price of $0.85 and a two-hundred day moving average price of $0.69.

About Starpharma

(Get Free Report)

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Starpharma Right Now?

Before you consider Starpharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Starpharma wasn't on the list.

While Starpharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover
10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.